UBS Group’s bioAffinity Technologies BIAFW Stock Holding History

UBS Group’s Portfolio BIAFW Stock Details BIAFW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.9K	Sell	46,109 -440	-0.9%	-$140	﹤0.01%	7900
2025 Q4	$16.3K	Sell	46,549 -1,120	-2%	-$400	﹤0.01%	7920
2025 Q3	$15.7K	Sell	47,669 -903	-2%	-$128	﹤0.01%	8308
2025 Q2	$6.31K	Buy	48,572 +289	+0.6%	+$51	﹤0.01%	9103
2025 Q1	$9.17K	Buy	48,283 +47,618	+7,161%	+$19.7K	﹤0.01%	8705
2024 Q4	$199	Buy	665 +198	+42%	+$167	﹤0.01%	9576
2024 Q3	$537	Buy	+467	New	+$485	﹤0.01%	8905
2023 Q3	–	Sell	-285	Closed	-$60	–	9466
2023 Q2	$60	Buy	+285	New	+$88	﹤0.01%	8579
2023 Q1	–	Sell	-66	Closed	-$28	–	9615
2022 Q4	$28	Sell	66 -11,646	-99%	-$5.13K	﹤0.01%	10531
2022 Q3	$4K	Buy	+11,712	New	+$12.1K	﹤0.01%	9331

Other funds holding BIAFW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group's BIAFW Position: Q1 2026 in Review

UBS Group reduced its bioAffinity Technologies (BIAFW) stake by 0.95% in Q1 2026, selling an estimated $140 and leaving 46,109 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7900.

UBS Group first reported a position in BIAFW in Q3 2022 and has held it in 10 quarters since. 4 funds tracked by Wall St. Rank hold BIAFW as of Q1 2026.

UBS Group held 46,109 shares of bioAffinity Technologies worth $20.9K as of Q1 2026.
UBS Group sold 440 bioAffinity Technologies shares in Q1 2026, an estimated $140.
bioAffinity Technologies made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7900 holding.
UBS Group first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 10 quarters since.
4 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.